Brigid Bonner
About Brigid Bonner
Brigid Bonner was appointed to Concentra Group Holdings Parent, Inc.’s Board of Directors effective July 1, 2025; she is a non-employee director eligible for director compensation as described in Concentra’s 2025 proxy statement . She is President of Bonner Consulting with 35+ years of senior executive experience across retail, technology, e-commerce, and health care, including roles at CaringBridge, UnitedHealth Group, IBM, Target, The Schwan Food Company, and SimonDelivers.com . She holds a B.S. from Iowa State University and an MBA from Harvard Business School . A Form 3 filed upon appointment reported no beneficial ownership of Concentra securities as of July 1, 2025 .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| CaringBridge | Senior leadership role | Not disclosed | Digital transformation, consumer experience focus |
| UnitedHealth Group | Senior leadership role | Not disclosed | Health care strategy; data-driven operations |
| IBM | Senior leadership role | Not disclosed | Technology and e-commerce initiatives |
| Target Corporation | Senior leadership role | Not disclosed | Retail and consumer experience strategy |
| The Schwan Food Company | Senior leadership role | Not disclosed | Business development initiatives |
| SimonDelivers.com | Senior leadership role | Not disclosed | Start-up/e-commerce operations |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Bonner Consulting | President | Current | Strategy, digital transformation, executive coaching |
Board Governance
- Appointment and term: Appointed June 26, 2025 (effective July 1, 2025); her term runs until the 2027 Annual Meeting, when she will stand for election along with other nominees .
- Independence/related-party: The 8-K states no related-party transactions for Ms. Bonner requiring disclosure under Item 404(a) . Concentra ceased “controlled company” status in Nov 2024 and is phasing to fully independent Compensation and Nominating committees by Nov 2025; Audit must be fully independent within one year of the IPO .
- Board composition and leadership: Board expanded to seven directors in June 2025; chairman is Robert A. Ortenzio; Daniel J. Thomas serves as Lead Director with defined responsibilities including presiding over executive sessions and liaising with independent directors .
- Committees and current membership (pre-appointment; subject to change): Audit & Compliance (Thomas—chair; Newton; Watkins) ; Human Capital & Compensation (Ortenzio—chair; Thomas; Pegus) ; Nominating, Governance & Sustainability (Ortenzio—chair; Watkins; Pegus) ; Quality of Care & Patient Safety (Pegus—chair; Watkins) . Ms. Bonner’s committee assignments were not disclosed in the appointment 8-K .
- Meetings/attendance policy: Board meets at least quarterly; in 2024 there were two board meetings with full attendance by then-current directors; directors are expected to attend annual meetings .
Fixed Compensation
Structure applicable to non-employee directors (Ms. Bonner is eligible per 8-K; actual amounts for her will reflect service timing):
| Component | Amount | Notes |
|---|---|---|
| Quarterly cash retainer | $12,500 | Directors may elect to receive retainer in fully-vested shares |
| Board meeting fee (in-person) | $3,000 per meeting | $4,000 if Audit & Compliance held independent of a Board meeting |
| Board meeting fee (telephonic) | $600 per meeting | Applies to telephonic attendance |
| Audit & Compliance Committee meeting fee (in-person) | $3,000 per meeting | $4,000 if independent of Board meeting |
| Audit & Compliance Committee meeting fee (telephonic) | $1,500 per meeting | — |
| Audit & Compliance Committee chair premium | $1,000 in-person; $500 telephonic per meeting | — |
| Quality of Care & Patient Safety Committee meeting fee (in-person) | $2,000 per meeting | $3,000 if independent of Board meeting |
| Quality of Care & Patient Safety Committee meeting fee (telephonic) | $1,000 per meeting | — |
| Other committee meeting fee (in-person) | $1,000 per meeting | $2,000 if independent of Board meeting |
| Other committee meeting fee (telephonic) | $500 per meeting | — |
Stock ownership guidelines for directors: Must own shares equal to five times annual cash compensation (excluding meeting fees), with three years to comply; guidelines recalculated annually .
Performance Compensation
Director equity program (structure at Concentra; Ms. Bonner will be eligible; her individual grant details were not disclosed at appointment):
| Item | Details |
|---|---|
| Annual/onboarding grant (Nov 26, 2024) | 12,992 restricted shares to each non-employee director |
| Vesting | 50% (onboarding grant) vests ratably over five years; 50% (annual grant) vests after one year |
| Grant-date price | $23.09 per share (basis for fair value calculation) |
| Fair value example (2024) | $299,985 per director stock awards for those serving in 2024 |
| Trading/hedging policy | Directors prohibited from hedging company securities (e.g., collars, swaps, derivatives) |
Note: Ms. Bonner’s 8-K specifies eligibility for non-employee director compensation as described in the proxy; her initial Form 3 reported no holdings as of July 1, 2025, and no Form 4 grant was found in filings reviewed .
Other Directorships & Interlocks
| Company | Role | Status |
|---|---|---|
| Public company boards | Not disclosed in Concentra filings reviewed | None disclosed |
| Related-party transactions | N/A | None requiring disclosure under Item 404(a) for Ms. Bonner |
Expertise & Qualifications
- Strategy and digital transformation leader with specialties in strategic planning, business development, consumer experience, and coaching; 35+ years across nonprofit, start-up, Fortune 100 organizations in health care, retail, technology, and e-commerce .
- Education: B.S. Iowa State University (journalism/advertising; industrial administration); MBA Harvard Business School .
- Appointed alongside Vipin Gopal to strengthen board capabilities in data, AI, technology, and customer experience as Concentra scales post-IPO .
Equity Ownership
| Filing | Date | Reported Beneficial Ownership | Notes |
|---|---|---|---|
| Form 3 (Initial Statement) | July 1, 2025 | 0 shares | Filed with a limited power of attorney appointing Timothy F. Ryan; no securities beneficially owned at appointment |
| Form 4 (Transactions) | Through Aug 2025 | None located | No Form 4 grant/disposition for Ms. Bonner found in reviewed filings [Search result: none] |
Director stock ownership guidelines: five times annual cash compensation; three-year compliance window; anti-hedging policy in effect for directors .
Governance Assessment
- Independence and conflicts: No related-party transactions disclosed for Ms. Bonner; appointed as a non-employee director with eligibility under standard director compensation policies—favorable for alignment and independence .
- Committee assignment transparency: No committee assignment disclosed at appointment; Concentra is in an NYSE phase-in to fully independent Compensation and Nominating committees by Nov 2025 and a fully independent Audit committee within one year of IPO—investors should monitor committee compositions and any leadership roles assigned to Ms. Bonner .
- Ownership alignment: Initial Form 3 showed no holdings; stock ownership guidelines require meaningful equity over three years, and anti-hedging enhances alignment—watch for future equity grants and accumulation consistent with guidelines .
- Board effectiveness context: Lead Independent Director structure, regular executive sessions, and established committee charters (including Quality of Care oversight) are positives for governance rigor; board expanded to seven directors in June 2025 to strengthen expertise relevant to Concentra’s data and customer-experience initiatives .